[Federal Register Volume 86, Number 220 (Thursday, November 18, 2021)]
[Notices]
[Pages 64481-64491]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-25150]


=======================================================================
-----------------------------------------------------------------------

FEDERAL TRADE COMMISSION

[File No. 191 0082; Docket No. C-4710]


Petition for Prior Approval of Sartorius Stedim Biotech S.A.'s 
Proposed Acquisition of Novasep Process SAS's Chromatography Equipment 
Business

AGENCY: Federal Trade Commission.

ACTION: Announcement of petition; request for comment.

-----------------------------------------------------------------------

SUMMARY: Sartorius Stedim Biotech S.A. (``Sartorius'') has petitioned 
the Federal Trade Commission (``FTC'' or ``Commission'') for approval 
of its acquisition of the chromatography equipment business of Novasep 
Process SAS. Sartorius was the FTC-approved divestiture buyer in 2020, 
when the FTC required Danaher Corporation to divest assets as a 
condition of acquiring General Electric's biopharmaceutical business, 
which included chromatography assets. Sartorius agreed to obtain the 
Commission's prior approval if it proposed to acquire Novasep's 
chromatography business.

DATES: Comments must be received on or before December 20, 2021.

ADDRESSES: Interested parties may file comments online or on paper, by 
following the instructions in the Request for Comment part of the 
SUPPLEMENTARY INFORMATION section below. Please write: ``Sartorius 
Petition for Prior Approval; Docket No. C-4710'' on your comment, and 
file your comment online at www.regulations.gov by following the 
instructions on the web-based form. If you prefer to file your comment 
on paper, please mail your comment to the following address: Federal 
Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, 
Suite CC-5610 (Annex D), Washington, DC 20580; or deliver your comment 
to the following address: Federal Trade Commission, Office of the 
Secretary, Constitution Center, 400 7th Street SW, 5th Floor, Suite 
5610 (Annex D), Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT: Lisa De Marchi Sleigh (202-326-2535), 
Bureau of Competition, Federal Trade Commission, 600 Pennsylvania 
Avenue NW, Washington, DC 20580.

SUPPLEMENTARY INFORMATION: Pursuant to FTC Rule 2.41(f), 16 CFR 
2.41(f), notice is hereby given that the public [redacted] version of 
the above-captioned petition has been filed with the Secretary of the 
Commission and is being placed on the public record for a period of 
thirty (30) days. After the period for public comments has expired, the 
Commission shall determine whether to approve the petition. In making 
its determination, the Commission will consider, among other 
information, all timely and responsive comments submitted in connection 
with this document.
    The text of the public [redacted] version of the petition is 
provided below. An electronic copy of the text of the public [redacted] 
version of the petition can be obtained from the FTC website at this 
web address: https://www.ftc.gov/enforcement/cases-proceedings/191-0082/danaher-corporation-matter.
    You can file a comment online or on paper. For the Commission to 
consider your comment, we must receive it on or before December 20, 
2021. Write ``Sartorius Petition for Prior Approval; Docket No. C-
4710'' on your comment. Your comment--including your name and your 
state--will be placed on the public record of this proceeding, 
including, to the extent practicable, on the www.regulations.gov 
website.
    Due to protective actions in response to the COVID-19 pandemic and 
the agency's heightened security screening, postal mail addressed to 
the Commission will be subject to delay. We strongly encourage you to 
submit your comments online through the www.regulations.gov website.
    If you prefer to file your comment on paper, write ``Sartorius 
Petition for Prior Approval; Docket No. C-4710'' on your comment and on 
the envelope, and mail your comment to the following address: Federal 
Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, 
Suite CC-5610 (Annex D), Washington, DC 20580; or deliver your comment 
to the following address: Federal Trade Commission, Office of the 
Secretary, Constitution Center, 400 7th Street SW, 5th Floor, Suite 
5610 (Annex D), Washington, DC 20024. If possible, submit your paper 
comment to the Commission by courier or overnight service.
    Because your comment will be placed on the publicly accessible 
website at www.regulations.gov, you are solely responsible for making 
sure your comment does not include any sensitive or confidential 
information. In particular, your comment should not include any 
sensitive personal information, such as your or anyone else's Social 
Security number; date of birth; driver's license number or other state 
identification number, or foreign country equivalent; passport number; 
financial account number; or credit or debit card number. You are also 
solely responsible for making sure your comment does not include any 
sensitive health information, such as medical records or other 
individually identifiable health information. In addition, your comment 
should not include any ``trade secret or any commercial or financial 
information which . . . is privileged or confidential''--as provided by 
Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 
16 CFR 4.10(a)(2)--including in particular competitively sensitive 
information such as costs, sales statistics, inventories, formulas, 
patterns, devices, manufacturing processes, or customer names.
    Comments containing material for which confidential treatment is 
requested must be filed in paper form, must be clearly labeled 
``Confidential,'' and must comply with FTC Rule 4.9(c). In particular, 
the written request for confidential treatment that accompanies the 
comment must include the factual and legal basis for the request, and 
must identify the specific portions of the comment to be withheld from 
the public record. See FTC Rule 4.9(c). Your comment will be kept 
confidential only if the General Counsel grants your request in 
accordance with the law and the public interest. Once your comment has 
been posted on www.regulations.gov--as legally required by FTC Rule 
4.9(b)--we cannot redact or remove your comment from that website, 
unless you submit a confidentiality request that meets the requirements 
for such treatment under FTC Rule 4.9(c), and the General Counsel 
grants that request.
    Visit the FTC website at http://www.ftc.gov to read this document 
and the news release describing this matter. The FTC Act and other laws 
that the Commission administers permit the collection of public 
comments to consider and use in this proceeding, as appropriate. The 
Commission will consider all timely and responsive public comments that 
it receives on or before December 20, 2021. For information on the 
Commission's privacy policy, including routine uses permitted by the 
Privacy Act, see

[[Page 64482]]

https://www.ftc.gov/site-information/privacy-policy.

Joel Christie,
Acting Secretary.

Petition for Prior Approval of Sartorius Stedim Biotech S.A.'s Proposed 
Acquisition of Novasep Process SAS's Chromatography Equipment Business

I. Introduction

    Pursuant to Section 2.41(f) of the Federal Trade Commission (the 
``FTC'' or the ``Commission'') Rules of Practice and Procedure \1\ and 
Section X(B) of the May 28, 2020 final decision and order in In the 
Matter of Danaher Corporation and General Electric Company (the 
``Danaher Order'' or ``Order''),\2\ Sartorius Stedim Biotech S.A. 
(``Sartorius'') hereby petitions the Commission to approve its proposed 
acquisition of the chromatography equipment business of Novasep Process 
SAS (``Novasep'' and, together with Sartorius, the ``Parties'') (the 
``Proposed Transaction'').
---------------------------------------------------------------------------

    \1\ 16 CFR 2.41(f).
    \2\ In the Matter of Danaher Corp. and General Electric Co., 
Decision and Order, Docket No. C-4710, (F.T.C. May 28, 2020), 
https://www.ftc.gov/system/files/documents/cases/191_0082_c4710_danaher_do_0.pdf (hereinafter, the ``Danaher 
Order''), at Sec.  X(B).
---------------------------------------------------------------------------

    The Commission's Order was entered to resolve competition concerns 
arising from Danaher Corporation's (``Danaher'') $21.4 billion 
acquisition of General Electric Company's (``GE'') biopharma business. 
Danaher and GE have been leading suppliers of manufacturing equipment 
and related products to the biopharma industry for many years. The FTC 
was concerned that combining Danaher's Pall Biotech and GE's Cytiva 
chromatography equipment product lines would create or reinforce 
dominant market positions in: (1) Conventional low pressure liquid 
chromatography (``LPLC'') columns; \3\ (2) conventional LPLC skids; \4\ 
(3) single-use (``SU'') LPLC chromatography skids; and (4) LPLC 
continuous chromatography systems.\5\ By requiring Danaher to divest to 
Sartorius the overlapping Pall Biotech products in these segments 
(collectively, the ``Pall Assets''), the FTC facilitated a new entrant 
in this important area of downstream biopharmaceutical 
manufacturing.\6\ In support of its determination that Sartorius would 
be a suitable purchaser of the Pall Assets and other Danaher divested 
assets, the Commission explained: ``Sartorius's existing biopharma 
business includes products that are highly complementary to the 
divestiture assets. Sartorius has the expertise, worldwide sales 
infrastructure, and resources to restore the competition that otherwise 
would have been lost due to the proposed Acquisition.'' \7\ Sartorius 
completed the acquisition on April 30, 2020.\8\
---------------------------------------------------------------------------

    \3\ ``Conventional LPLC columns are containers that hold 
chromatography resins used as the adsorbent during the stationary 
phase. Columns are made of glass, stainless steel, acrylic glass, or 
plastic[.]'' In the Matter of Danaher Corp. and General Electric 
Co., Complaint at ] III(5)(b), Docket No. C-4710 (F.T.C. Mar. 19, 
2020), https://www.ftc.gov/system/files/documents/cases/191_0082_c4710_danaher_ge_complaint.pdf (hereinafter, the ``Danaher 
Complaint'').
    \4\ ``Conventional LPLC skids control the flow of liquid in the 
chromatography process. Conventional LPLC skids contain a system of 
pumps, valves, sensors, tubing, electronic components, software, and 
flow paths composed of multi-use components[.]'' Danaher Complaint, 
at ] III(5)(c).
    \5\ ``LPLC continuous chromatography systems allow for the 
simultaneous processing of multiple columns in LPLC. LPLC continuous 
chromatography systems consist of pumps, valves, sensors, tubing, 
electronic components, software, and flow paths composed of either 
multi-use or single-use components[.]'' Danaher Complaint, at ] 
III(5)(f). ``While continuous chromatography has for some time been 
an accepted practice by small-molecule manufacturers, it is not yet 
[as] widely used in larger bio-manufacturing processes.'' European 
Commission: DG Competition, Danaher/GE Healthcare Life Sciences 
Biopharma, Case M.9331, Commission Decision, at ] 367, https://ec.europa.eu/competition/mergers/cases/decisions/m9331_3668_3.pdf 
(last visited Oct. 22, 2021) (hereinafter, ``European Commission 
Decision'').
    \6\ See Danaher Order at Sec.  I(N); Danaher Complaint, at ] 5.
    \7\ In the Matter of Danaher Corp. and General Electric Co., 
Analysis of Agreement Containing Consent Orders to Aid Public 
Comment. at 5, Docket No. C-4710, File No. 191-0082 (F.T.C.), 
https://www.ftc.gov/system/files/documents/cases/191_0082_danaher-ge_aapc.pdf (last visited Oct. 22, 2021).
    \8\ Sartorius closes acquisition of selected assets of Danaher 
Life Sciences, Sartorius (Apr. 30, 2020), https://www.sartorius.com/en/company/newsroom/corporate-news/483898-483898.
---------------------------------------------------------------------------

    As a new entrant in the chromatography equipment business, 
Sartorius is playing ``catch up'' with incumbent chromatography 
suppliers that have long dominated the industry, including Danaher/GE, 
Merck Millipore, and Thermo Fisher. To compete with these incumbent 
suppliers, which benefit from an extensive installed base of 
chromatography equipment, Sartorius must offer customers a range of 
innovative products and disruptive technologies that generate 
significant productivity gains and cost savings to justify customers 
replacing their existing legacy equipment.\9\
---------------------------------------------------------------------------

    \9\ See SART_0002159--SART_0002187, at SART_0002173 (comparing 
projected customer cost savings of the Parties' jointly developed 
BioSC-RCC system to GE/Cytiva's conventional LPLC batch equipment).
---------------------------------------------------------------------------

    By bringing together the Parties' largely complementary 
chromatography equipment businesses and technologies, the Proposed 
Transaction will accelerate Sartorius's efforts to commercialize 
disruptive technologies needed to achieve a more efficient, more 
productive, and lower cost drug and vaccine production infrastructure 
that will improve healthcare outcomes and benefit consumers throughout 
the U.S. and around the world.

a. Background to the Proposed Transaction

    Through the Proposed Transaction, the Parties will be able to 
achieve innovations in biopharma manufacturing that are necessary to 
bring new drugs and vaccines to market more quickly, cost-effectively, 
and equitably. The COVID-19 pandemic has underscored the critical 
importance of having a robust biopharma infrastructure to combat new 
viruses and diseases. There is a need for innovative manufacturing 
processes that are capable of developing and mass-producing new drugs 
and vaccines rapidly and cost-effectively. Although the biopharma 
industry quickly rose to the challenge of developing biologic therapies 
and vaccines to ameliorate the severity of COVID-19, those medical 
breakthroughs were not available on a large scale to populations in the 
U.S. and around the world in time to avoid significant loss of human 
life. New COVID-19 variants and novel diseases will remain an ongoing 
public health concern, and the biopharma industry needs to be able to 
respond quickly, equitably, and efficiently to address these threats to 
public health and economic security around the world.
    To ensure that all members of the population have timely access to 
life saving drugs and vaccines at reasonable cost, disruptive 
technologies are needed to remove bottlenecks in biopharma drug and 
vaccine development and manufacturing. One of the primary roadblocks to 
achieving this goal with protein-based therapies is that ``downstream'' 
biopharma production--the purification of cell mass to eliminate 
contaminants and unwanted viruses that occurs after the ``upstream'' 
process of discovery, development, and growth of therapeutic cell 
mass--is still a relatively inefficient process. These inefficiencies 
inhibit the biopharma industry from being able to provide patients with 
rapid access to life saving therapies and provide new vaccines to 
entire populations on a large scale. For decades, downstream 
chromatography has been performed using conventional ``batch'' LPLC 
equipment packed with specialized, costly resins (such as Protein A 
resins) to purify the product. This process does not utilize resins 
efficiently, and significant volumes are

[[Page 64483]]

wasted in the process.\10\ Furthermore, each of the up to four 
downstream chromatography steps are performed using separate equipment, 
which results in additional inefficiencies and bottlenecks.\11\
---------------------------------------------------------------------------

    \10\ See SART_0016472, at 19 (indicating customers' most 
significant chromatography challenges include the high cost 
associated with the inefficient use of resins, the relatively slow 
speed of conventional batch chromatography, and the large spaces 
within manufacturing facilities required to house conventional batch 
chromatography equipment).
    \11\ See infra Section III(c)(i).
---------------------------------------------------------------------------

    The leading incumbent suppliers of conventional LPLC systems--
including Danaher/GE, Merck Millipore, and Thermo Fisher--also have 
resin supply businesses (including the costly Protein A resin) that are 
highly profitable and generate very significant recurring revenues. 
These incumbent suppliers are incentivized to maintain the status quo 
to protect their installed base of conventional LPLC equipment and the 
significant recurring resin revenues they generate. As a result, they 
have not aggressively pursued innovations in downstream chromatography 
that are necessary to address the bottlenecks that inhibit the rapid 
and cost-effective development and production of biologic drugs and 
vaccines. New disruptive technologies are required to replace this 
installed base of resin-dependent legacy chromatography equipment with 
innovative equipment and technologies that reduce (and ultimately will 
eliminate) bottlenecks.
    The acquisition will allow Sartorius to accelerate the development 
and commercialization of ``intensified'' LPLC chromatography systems as 
platforms for innovation to support the biopharma industry's need to 
develop and commercialize lifesaving vaccines and biologic drugs faster 
and at lower cost.

b. The Sartorius-Novasep Collaboration

    Sartorius is a disruptor to the resin industry and a new entrant in 
the chromatography equipment business that must continue to innovate to 
successfully compete with larger incumbent suppliers. For the past 
several years, Sartorius has been pursuing a strategic collaboration 
with Novasep that utilizes Sartorius's disruptive membrane technology, 
Sartobind (which eliminates the need for costly resins), with Novasep's 
innovative LPLC continuous chromatography system, BioSC (which combines 
several downstream processing steps in one platform). The innovative 
product development that Sartorius and Novasep have been pursuing 
through their collaboration offers the potential for significant 
productivity gains and cost savings in the development and production 
of biopharma drugs and vaccines. Notably, the Parties have developed a 
unique new product, BioSC-RCC, an intensified chromatography system 
that eliminates the need for resin, which is currently in customer 
trials.
    After the collaboration was already well advanced, Novasep made a 
strategic decision to exit the chromatography equipment business for 
reasons that are further explained in Section II below.\12\ Novasep 
viewed Sartorius as the natural acquirer of the business because 
Sartorius was already utilizing Novasep's LPLC continuous 
chromatography system (BioSC) as a platform for its innovative membrane 
technology.\13\ Since Novasep had decided to exit and sell the 
business, both Parties concluded that acquiring the business was the 
only way to preserve the fruits of the collaboration, and achieve 
further innovations utilizing a combination of Novasep and Sartorius 
technologies, know-how, and equipment.
---------------------------------------------------------------------------

    \12\ See Rebecca H. Farrington Letter to Lisa DeMarchi Sleigh, 
dated August 9, 2021 (regarding Novasep's decision to exit the 
chromatography equipment business).
    \13\ Id. at 6-7; see also NOVA-002147, at NOVA-002147 
(containing Novasep Holding Meeting Minutes from November 20, 2020).
---------------------------------------------------------------------------

    Due to the accelerated timing of the Pall Asset divestitures, 
Sartorius acquired the Pall Assets before finalizing its agreement to 
acquire Novasep's chromatography equipment business. The Pall Assets 
include BioSMB, a LPLC continuous chromatography system that offers 
some of the same process intensification capabilities as BioSC. Because 
the Novasep acquisition was not reportable under the Hart-Scott-Rodino 
Act, Sartorius agreed to provide the FTC an opportunity to review the 
transaction and not to close without the Commission's prior 
approval.\14\
---------------------------------------------------------------------------

    \14\ Danaher Order at Sec. Sec.  II(A), X(B).
---------------------------------------------------------------------------

c. The Proposed Transaction

    On March 2, 2021, following approval by Novasep's French Works 
Council, the Parties executed a share and asset purchase agreement 
(``SAPA'') to sell Novasep's chromatography equipment business to 
Sartorius.\15\ To effectuate the Proposed Transaction, Novasep has 
contributed the assets that comprise its chromatography business in 
France to a NewCo that Sartorius will acquire in a stock purchase 
transaction, in addition to assets that comprise Novasep's U.S. and 
Chinese chromatography businesses. Both Parties have received uniformly 
positive feedback from customers who view Sartorius as an innovative 
supplier that will be able to overcome the challenges that Novasep has 
experienced with its LPLC business.\16\
---------------------------------------------------------------------------

    \15\ SART_0001673--SART_0002117.
    \16\ See, e.g., SART_0171028 (customer letter in support of 
transaction); NOVA-002483--NOVA-002484; NOVA-002485; NOVA-002486 
(customer declarations in support of transaction).
---------------------------------------------------------------------------

d. The PharmaZell-Novasep Transaction

    On September 16, 2021, Novasep announced it had entered into 
exclusive negotiations to create a common platform in the contract 
development and manufacturing organization (``CDMO'') space through a 
proposed merger with PharmaZell.\17\ The transaction excludes Novasep's 
chromatography equipment business, which is not a strategic fit with 
PharmaZell's or Novasep's CDMO businesses.\18\ PharmaZell has no 
interest in acquiring Novasep's chromatography equipment business if 
the sale to Sartorius does not proceed. In that event, the 
chromatography equipment business (the French portion of which has 
already been transferred to a NewCo in preparation for the sale to 
Sartorius) would be transferred to NVHL S.A., a non-operating holding 
company owned by Novasep's private investors, which include funds 
focused on credit and special situations investments.
---------------------------------------------------------------------------

    \17\ See PharmaZell and Novasep enter into exclusive 
negotiations in new drive to create a technology-driven leader for 
complex small molecules and ADCs of global scale, PharmaZell (Sept. 
16, 2021), https://pharmazell-group.com/blog/2021/09/16/pharmazell-and-novasep-enter-into-exclusive-negotiations-in-new-drive-to-create-a-technology-driven-leader-for-complex-small-molecules-and-adcs-of-global-scale/.
    \18\ See Rebecca H. Farrington Letter to Lisa DeMarchi Sleigh, 
dated October 7, 2021 (regarding proposed PharmaZell-Novasep 
transaction).
---------------------------------------------------------------------------

e. Procompetitive Effects of the Proposed Transaction

    As described further in Section III below, as a result of the 
Proposed Transaction:
     Novasep's high pressure liquid chromatography (``HPLC'') 
equipment, which is used for the production of small molecules, and 
LPLC equipment will be supported by a manufacturer with a reputation 
for producing high quality innovative products and a global marketing, 
sales and service infrastructure. As part of Sartorius's broader 
product portfolio and global sales and service infrastructure, 
Novasep's chromatography business will have a stronger platform for 
commercial success.

[[Page 64484]]

    [cir] The benefits will be particularly pronounced in the U.S. 
where Sartorius has a robust sales and service infrastructure and 
Novasep has very limited presence.
     All of Novasep's chromatography equipment product lines 
will benefit from Sartorius's more efficient manufacturing and 
distribution, greater security of supply, and accelerated delivery 
times, which will increase their competitiveness and penetration with 
new customers and in new applications.
     The Parties' LPLC continuous chromatography systems are 
differentiated products that virtually never compete directly.
    [cir] Sartorius's BioSMB system and Novasep's BioSC system are 
based on different technologies that provide process intensification in 
different ways and meet distinct customer needs and manufacturing 
strategies.
     As a disruptor and new entrant in a space with strong 
incumbents and increasing competition, Sartorius has a strong incentive 
to continue to invest in and innovate with both of the differentiated 
process intensification platforms it will be offering to biopharma 
customers: BioSC and BioSMB.
    [cir] Sartorius's product roadmap and research and development 
plans demonstrate that Sartorius will continue to support, enhance, and 
innovate with both of these platforms.
    [cir] Sartorius also has made specific commitments to the French 
government to maintain and invest in Novasep's chromatography equipment 
business and retain its employees.\19\
---------------------------------------------------------------------------

    \19\ See Andrew S. Wellin Letter to Lisa DeMarchi Sleigh, dated 
July 1, 2021 (regarding Sartorius's commitments in connection with 
French foreign investment approval of the Proposed Transaction).
---------------------------------------------------------------------------

     The transaction poses no risk to competition in HPLC 
columns or skids as Sartorius has no HPLC product offering.
     The transaction similarly poses no risk to competition in 
conventional LPLC columns or skids because Novasep has de minimis sales 
and market shares in these products.

II. The Parties and the Transaction Rationale

a. The Parties

i. Sartorius
    Sartorius is a supplier of innovative, cost-effective technologies 
and products that accelerate biopharma development and increase the 
speed, efficiency, and safety of biopharma production. Sartorius's 
Bioprocessing Solutions Division (``BPS'') supports all phases of 
biopharmaceutical product development, from early phase development to 
commercial manufacturing, from cell line development to process 
development, including upstream and downstream processing. Sartorius's 
innovative membrane technology (Sartobind) eliminates the use of resins 
in certain downstream chromatography processing steps--a significant 
advance that holds the promise of improving the efficiency and reducing 
the cost of developing and manufacturing biologic drugs and vaccines, 
compared to traditional batch chromatography systems.\20\
---------------------------------------------------------------------------

    \20\ SART_0006206, at 5, 12 (indicating that Sartobind Rapid A 
membranes have significantly higher productivity than Protein A 
resins and can be easily scaled up for commercial production). 
Sartorius's membrane innovations have the potential to be a 
significant disrupter to traditional resin suppliers, led by Danaher 
(Cytiva), which has an estimated 75% market share in Protein A 
resin.
---------------------------------------------------------------------------

    Sartorius has a worldwide presence with manufacturing, sales, and 
research and development (``R&D'') sites in more than 20 countries in 
Europe, North America, and Asia. Sartorius also has expertise in SU 
bioprocessing technologies, including LPLC equipment, as well as in 
value-added automation technology and software, which it uses to meet 
the evolving technology needs of its large molecule biopharma 
customers.
ii. Novasep
    Novasep is a provider of services, equipment, and ingredients to 
the pharmaceutical, chemical, and food industries. Novasep's core focus 
and competency is its CDMO business, which accounts for over [REDACTED] 
of its overall revenues. Novasep's much smaller chromatography 
equipment business is focused on supporting the development and 
production of smaller molecule drugs and applications.
    From its historic roots in food production, Novasep has developed 
expertise in multi-use (``MU'') HPLC equipment, which is used in the 
production of small molecule drugs. Novasep derives a high proportion 
(75-85%) of its chromatography equipment revenue and profits from the 
sale of HPLC equipment.\21\ Novasep's LPLC equipment business, by 
contrast, is very small, as Novasep has struggled to penetrate 
biopharma customers. Novasep's equipment utilizes MU technology, which 
is cleaned and then re-used in different bioprocessing production runs. 
Many biopharma customers increasingly require equipment that uses SU 
flow-paths for manufacturing at commercial scale. Novasep has no 
expertise in the plastics technologies required to produce SU (i.e., 
disposable) flow-paths and has been unable to develop a SU flow-path 
for BioSC or its other LPLC equipment.\22\ Novasep's LPLC business is 
not profitable on a standalone basis, and has declined over the last 
several years.\23\
---------------------------------------------------------------------------

    \21\ See NOVA-Appendix 13-00000095, at NOVA-Appendix 13-
00000098; NOVA-Appendix 13-00000143, at NOVA-Appendix 13-00000147.
    \22\ See Rebecca H. Farrington Letter to Lisa DeMarchi Sleigh, 
dated August 9, 2021, at 5-6 (regarding Novasep's decision to exit 
the chromatography equipment business); Rebecca H. Farrington Letter 
to Lisa DeMarchi Sleigh, dated October 4, 2021 (regarding Novasep's 
inability to develop a SU flow-path); NOVA-000872, at NOVA-000875, 
NOVA-000881 (Budget 2020 BU Process Solutions, October 30, 2019); 
NOVA-000691, at NOVA-000703 (Budget 2021 Equipment Solutions, 
December 22, 2020); NOVA-000783, at NOVA-000796 (Novasep Business 
Review, April 2020); SART_0000526--SART_0000538, at SART_0000533 
(stating Novasep's ``[i]nability to develop SU flowpath has 
challenged business growth especially in North America.''); NOVA-
001091--NOVA-001097, at NOVA-001095.
    \23\ See NOVA-Appendix 13-00000001, at NOVA-Appendix 13-
00000004; NOVA-Appendix 13-00000048, at NOVA-Appendix 13-00000051; 
NOVA-Appendix 13-00000095, at NOVA-Appendix 13-00000098; NOVA-
Appendix 13-00000143, at NOVA-Appendix 13-00000147; see also Rebecca 
H. Farrington Letter to Lisa DeMarchi Sleigh, dated October 8, 2021 
(regarding Novasep's financial condition).
---------------------------------------------------------------------------

b. The Transaction Rationale

    In 2019, Novasep made a strategic decision to exit the 
chromatography equipment business. Novasep has had significant 
financial and operational challenges with the business,\24\ which is 
highly capital intensive and lacks synergies with its core CDMO 
business. As mentioned above, Novasep's chromatography equipment 
business generates 75-85% of its revenues from sales of HPLC equipment 
used in small molecule drug production.\25\ To address the increasing 
importance of biopharmaceutical medicine, Novasep also has developed 
LPLC equipment for larger molecule biopharma drug and vaccine 
production. However, Novasep has been unable to gain traction with 
larger biomolecule customers and applications. Thus, its LPLC business 
remains very small. Novasep's lack of SU technology, which many 
biopharma customers (particularly in North America) prefer for drug and 
vaccine manufacturing at clinical and commercial scales, also has 
hampered

[[Page 64485]]

its efforts to develop the LPLC business.\26\
---------------------------------------------------------------------------

    \24\ See e.g., NOVA-VAL-0028970 at 2; NOVA-VAL-0028981, at 2; 
NOVA-VAL-0039971, at 3; see generally Rebecca H. Farrington Letter 
to Lisa DeMarchi Sleigh, dated August 9, 2021 (regarding Novasep's 
decision to exit the chromatography equipment business).
    \25\ See NOVA-Appendix 13-00000095, at NOVA-Appendix 13-
00000098; NOVA-Appendix 13-00000143, at NOVA-Appendix 13-00000147.
    \26\ See Rebecca H. Farrington Letter to Lisa DeMarchi Sleigh, 
dated August 9, 2021, at 5-6 (regarding Novasep's decision to exit 
the chromatography equipment business); see also Rebecca H. 
Farrington Letter to Lisa DeMarchi Sleigh, dated October 4, 2021 
(regarding Novasep's inability to develop a SU flow-path); NOVA-
000691--NOVA-000748, at NOVA-000708 (Budget 2021 Equipment 
Solutions).
---------------------------------------------------------------------------

    In sum, Novasep concluded that it did not have the 
infrastructure,\27\ reputation, or SU technology to grow its LPLC 
business successfully on its own. Furthermore, because Novasep is 
dependent on equipment sales, which are lumpy and unpredictable, and 
Novasep lacks a consumables business that would generate regular 
recurring revenues, Novasep has been unable to make the necessary 
investments to update its LPLC product line or develop next generation 
chromatography technologies, despite customer needs and requests for SU 
technology.\28\ Given these challenging financial dynamics and the 
significant ongoing capital needs of its chromatography equipment 
business, Novasep realized that it would continue to lose competitive 
ground in an increasingly competitive space if it held on to this 
business.\29\ In contrast, selling the equipment business to Sartorius 
would allow Novasep to focus resources on its core CDMO business.
---------------------------------------------------------------------------

    \27\ For example, Novasep has limited customer service and 
support. See, e.g., NOVA-VAL-0000079; NOVA-VAL-0014556; NOVA-VAL-
0018504; NOVA-VAL-0025513; NOVA-VAL-0027911; NOVA-VAL-0063924; NOVA-
VAL-0063984; NOVA-VAL-0073282; NOVA-VAL-0073557; NOVA-VAL-0075029 
(documents discussing software challenges, December 22, 2020).
    \28\ See NOVA-000001, at NOVA-000039 (Novasep Strategy 
Discussions and Options, July 2019). See also, e.g., NOVA-001208, at 
NOVA-001208, NOVA-001209; NOVA-VAL-0027941; NOVA-VAL-0038766; NOVA-
VAL-0040141.
    \29\ See Rebecca H. Farrington Letter to Lisa DeMarchi Sleigh, 
dated August 9, 2021, at 2-3 (regarding Novasep's decision to exit 
the chromatography equipment business).
---------------------------------------------------------------------------

i. The Proposed Transaction is Necessary To Protect the Fruits of the 
Parties' Collaboration
    Sartorius's acquisition of Novasep's chromatography equipment 
business was a natural evolution of the Parties' multi-year 
collaboration to develop innovative alternatives to the legacy batch 
chromatography equipment that is dependent on the use of resin, which 
is often supplied by incumbent chromatography equipment suppliers. 
These incumbent suppliers, including Danaher/GE, Merck Millipore, and 
Thermo Fisher, generate significant revenues and profits from the sale 
of costly resins, such as Protein A, required for the batch 
chromatography process. Protein A, which is required for the production 
of monoclonal antibody (``mAb'') drug therapies (e.g., COVID antibody 
``cocktails''), can cost anywhere from $5,000 to $16,000 per liter.
    Sartorius's collaboration with Novasep already has produced a new 
product--BioSC-RCC--that utilizes Novasep's BioSC LPLC continuous 
chromatography system as a platform for Sartorius's innovative membrane 
technology. BioSC-RCC provides an alternative to resin-based 
chromatography, and promises to accelerate the speed and efficiency of 
large molecule discovery and production, while greatly reducing process 
risk and cost.
    To accelerate access to this disruptive new product, the Parties 
initially developed and launched BioSC-RCC MU, which utilizes BioSC's 
existing BioSC platform and MU technology. BioSC-RCC MU is currently 
being tested by potential customers, who have shown strong interest in 
this unique new product that eliminates the need for costly resin and 
offers productivity gains, and cost and process risk reductions. 
However, to convert customer interest to actual sales, many of these 
potential customers will need to be assured that Sartorius will develop 
a BioSC-RCC version with a SU flow-path that they can use at larger 
scales. Once the transaction closes, Sartorius will be able to move 
forward with the development of a SU flow-path for the BioSC-RCC system 
and launch a SU version (BioSC-RCC SU) in 2022.\30\
---------------------------------------------------------------------------

    \30\ See SART_0000487--SART_0000498, at SART_0000498; 
SART_0001130--SART_1177, at SART_0001151 (Sartorius's acquisition 
business case assumes a multiyear investment in the development of a 
SU flow-path for BioSC RCC); id. at SART_0001171 (Sartorius's 
acquisition business plan assumptions include sales projections for 
SU BioSC-RCC systems).
---------------------------------------------------------------------------

    Although Sartorius was willing to make the investments to develop a 
prototype of BioSC-RCC MU pursuant to the collaboration, transforming 
the BioSC-RCC prototype into a commercially viable product has been 
(and will continue to be) challenging absent the Proposed Transaction 
due, in part, to Novasep's high cost of manufacturing BioSC, which 
limits the return on investment required to launch and maintain a new 
product long term.\31\
---------------------------------------------------------------------------

    \31\ See SART_0063502 (Sartorius BioSC-RCC margin calculations).
---------------------------------------------------------------------------

    Furthermore, the BioSC platform needs substantial upgrades and 
enhancements before any BioSC system (BioSC or BioSC-RCC) can be 
successfully commercialized. While BioSC utilizes an innovative 
continuous chromatography process and its integrated architecture works 
well with Sartorius's rapid cycling chromatography (``RCC'') process 
and membrane technology, it has suffered from years of underinvestment. 
In addition to its lack of a SU flow-path, there have been ongoing 
challenges with its software (which is supplied by GE/Cytiva), the lab 
scale version of the system does not easily ``scale up'' to clinical 
and commercial scale versions of the system, and its engineered-to-
order design and manufacturing process does not meet biopharma customer 
preferences for off-the-shelf systems with accelerated delivery times. 
The investments required to address these problems with the BioSC 
platform are beyond Sartorius's ability to address in the context of 
the Parties' collaboration because Sartorius does not own the platform, 
and in the case of BioSC-RCC MU has limited, short-term marketing 
rights and, for a potential BioSC-RCC SU version, no rights at all.\32\
---------------------------------------------------------------------------

    \32\ See generally SART_0002268--SART_0002303 (Collaboration 
Interim Manufacturing and Marketing Agreement).
---------------------------------------------------------------------------

    While Sartorius believes that the development of a SU flow-path, 
redesign of BioSC lab to easily scale up, standardization of the 
platform and manufacturing process, and software improvements will 
allow BioSC and BioSC-RCC to be commercially successful,\33\ these 
investments only make sense if Sartorius has the ability to achieve the 
necessary innovations and recoup its investment. Sartorius cannot 
achieve these innovations or recoup its investment in a system it does 
not own and, therefore, has no ability to redesign, manufacture, market 
or sell.
---------------------------------------------------------------------------

    \33\ See SART_0000539, at ``EUR Summary'' tab (Sartorius 
discounted cash flow analysis prepared for transaction valuation 
purposes indicating accelerating BioSC/BioSC-RCC growth due to 
investments).
---------------------------------------------------------------------------

    The acquisition of Novasep's chromatography equipment business is 
critical to successfully commercializing those innovations. Unless the 
acquisition is approved, the innovations the Parties have already 
developed (and plan to pursue after the acquisition) very likely will 
be lost. The ``winners'' will be incumbent suppliers, who will remain 
immune from disruptive technologies that would erode their installed 
base of outdated and inefficient equipment. The biggest ``losers'' will 
be biopharma producers and consumers who need new and improved 
biopharma manufacturing infrastructure to provide timely, efficient, 
and cost-effective access to new drugs and vaccines to address

[[Page 64486]]

public health risks and keep economies functioning well.
ii. The Proposed Transaction Will Enhance Sartorius's Competitiveness 
as a New Entrant That Competes Through Innovation
    Sartorius's acquisition of Novasep's chromatography equipment 
business will provide complementary technologies and expertise to 
``fill in the gaps'' in Sartorius's newly acquired downstream LPLC 
bioprocessing equipment portfolio.\34\
---------------------------------------------------------------------------

    \34\ See SART_0160423, at 2 (explaining how Sartorius is 
positioning itself to provide customers with more options in 
intensified downstream processing in a highly competitive 
environment of large, established players, where technology progress 
is already pointing towards continuous manufacturing); SART_0115519, 
at 12 (July 2021 BioSMB Business Plan projecting distinct growth 
rates for BioSC, BioSMB, and BioSC RCC).
---------------------------------------------------------------------------

    The acquisition of Novasep's HPLC equipment will enable Sartorius 
to offer customers a complete range of technologies for the 
purification of smaller molecules, complementing Sartorius's LPLC 
equipment that serves larger molecule biopharma manufacturing. 
Historically, Novasep's HPLC equipment was predominantly used to purify 
smaller molecule active ingredients and insulin. Recently, Novasep's 
HPLC equipment has played a critical role in the purification of key 
components of mRNA and recombinant protein COVID vaccines. Through its 
extensive sales and service network, Sartorius will be able to expand 
the reach and availability of Novasep's HPLC equipment across the 
globe, offer a full line of LPLC and HPLC equipment for customers who 
prefer to purchase from one source, and provide more choices in 
equipment and services for producers of life-saving drug therapies and 
vaccines.
    In addition to supporting and enhancing Novasep's HPLC business, 
the acquisition will enable Sartorius to successfully commercialize 
BioSC, Novasep's LPLC ``multistep'' intensified chromatography system, 
an innovative technology that Novasep has struggled to commercialize, 
particularly in North America, for reasons that include its limited 
sales presence, lack of SU technology, and inability to invest in 
necessary improvements and innovations (see further Section III(c)(ii) 
below). BioSC has achieved very few sales at the clinical or commercial 
scale, and sales have stagnated. Biopharma customers are making 
decisions today about investments in their manufacturing infrastructure 
for decades to come. Absent the Proposed Transaction and the investment 
and innovation Sartorius is uniquely placed to make to transform BioSC 
into a commercially attractive option, customers will miss a critical 
window to realize BioSC's potential to improve the downstream biopharma 
manufacturing process.

c. FTC Procedural History

    The FTC has conducted an extensive investigation of Sartorius's 
proposed acquisition of Novasep's chromatography equipment business. 
Sartorius provided an initial briefing on the Proposed Transaction in 
July 2020 and formally notified the transaction on January 21, 2021. 
The Parties have voluntarily produced numerous documents, data and 
submissions to the FTC, and regularly addressed staff questions as they 
arose in their investigation of the Proposed Transaction. In addition, 
Sartorius and Novasep management presented to, and were interviewed by, 
FTC staff. Both before and in response to the FTC's Voluntary Access 
Letters (``VALs'') issued in June 2021, Sartorius and Novasep each 
produced thousands of ordinary course business documents and data, and, 
at the FTC's request, both parties certified substantial compliance 
with the VALs.
    Now that the FTC staff have completed their investigation, the 
Parties submit this petition requesting the Commission's approval to 
permit the transaction to close before year end. In addition to 
enabling the Parties to meet their contractual obligations and 
transaction timetable, permitting closing before year end will 
eliminate the state of uncertainty that has hung over the Novasep 
chromatography equipment business for the past year, further business 
deterioration, and the ongoing challenge of retaining critical 
employees while the business is in limbo. Furthermore, essential 
innovation, including the completion of the development of the SU flow-
path for BioSC-RCC and BioSC, along with necessary software 
improvements \35\ and innovative product development for the BioSC 
system and other projects cannot be achieved until the transaction has 
closed. In the event that approval is not obtained by mid-December, 
Novasep likely will be forced to transfer the business back to its 
private investor shareholders, in which case the business will operate 
with even fewer financial and organizational resources than it has 
today.
---------------------------------------------------------------------------

    \35\ See NOVA-VAL-0000079; NOVA-VAL-0014556; NOVA-VAL-0018504; 
NOVA-VAL-0025513; NOVA-VAL-0027911; NOVA-VAL-0063924; NOVA-VAL-
0063984; NOVA-VAL-0073282; NOVA-VAL-0073557; NOVA-VAL-0075029 
(documents discussing software challenges). See also Rebecca H. 
Farrington Letters to Lisa DeMarchi Sleigh, dated September 15, 2021 
and October 5, 2021.
---------------------------------------------------------------------------

    Permitting the transaction to close before year end will enable the 
Novasep and Sartorius product development engineers to integrate and 
work together as a single team to move forward with product development 
and other innovations that cannot be achieved in the Parties' 
collaboration. Most importantly, approving the transaction before year 
end will ensure that customers and consumers benefit from the 
innovation resulting from new product launches and necessary 
improvements to existing products, which will be further delayed if the 
deal does not close by year end (and very likely will be lost 
altogether if the transaction is not approved).

III. The Transaction Is Procompetitive and Will Not Lessen Competition 
in Any Relevant Chromatography Market

    As the Commission alleged in the Danaher Complaint, ``[t]he 
relevant geographic area in which to assess the competitive effects of 
the Acquisition [of chromatography equipment] is no narrower than the 
United States and may be as broad as the entire world.'' \36\
---------------------------------------------------------------------------

    \36\ Danaher Complaint at ] III(6).
---------------------------------------------------------------------------

    As described further below, the acquisition of Novasep's HPLC 
column and skid assets will not lessen competition because Sartorius 
does not manufacture or sell HPLC equipment. Similarly, although 
Sartorius and Novasep each manufacture and sell conventional LPLC 
columns and skids, Novasep's sales and market share in each of these 
products is very small. Finally, the addition of Novasep's LPLC 
intensified chromatography system (BioSC) to Sartorius's product 
portfolio will be procompetitive because BioSC and Sartorius's BioSMB 
systems are complementary, highly differentiated products that meet 
distinct customer needs.\37\
---------------------------------------------------------------------------

    \37\ The segmentation of approaches to intensified/continuous 
LPLC chromatography between single-step and multistep solutions, 
demonstrates that customer demand exists for both intensification 
approaches, which will incentivize Sartorius to continue innovating 
with both BioSC and BioSMB platforms following the transaction. 
[REDACTED]. See SART_0000601--SART_0000605 (regarding Sartorius's 
plans to continue to support both systems).
---------------------------------------------------------------------------

a. HPLC Columns and Skids

    Sartorius's acquisition of Novasep's HPLC equipment fills a gap in 
its chromatography equipment portfolio and enhances Sartorius's ability 
to compete with incumbent chromatography equipment suppliers

[[Page 64487]]

that offer a full range of HPLC and LPLC equipment. By expanding its 
product portfolio, Sartorius will be able to serve customers who prefer 
to source their HPLC and LPLC equipment needs from a single supplier 
and give them more competitive choices.
    Novasep's HPLC equipment will allow Sartorius to offer a complete 
range of technologies for both the needs of the biopharma industry and 
adjacent pharmaceutical segments. The availability of Novasep's HPLC 
offerings alongside LPLC solutions from a single source also will allow 
Sartorius to achieve economies of scale and conform control systems 
across platforms.
    Following the acquisition, Sartorius will have every incentive to 
support and enhance Novasep's HPLC equipment. In addition to 
purification of small molecule active ingredients and insulin, 
Novasep's HPLC equipment is increasingly being used in COVID-19 vaccine 
development. For example, Novasep's Hipersep Pilot skid is being used 
to purify COVID-19 vaccine components, including the mRNA strands and 
lipid nanoparticles that are critical to the vaccines' efficacy. With 
its robust global marketing, sales and service infrastructure, 
Sartorius will be able to increase sales and penetration of Novasep's 
HPLC product lines with new customers and in new applications, 
including supporting vaccine producers' efforts to combat the COVID-19 
pandemic.

b. Conventional LPLC Columns and Skids

    As alleged in the FTC's Danaher Complaint, conventional LPLC column 
and skid markets have ``only three significant suppliers'': Danaher, GE 
and Merck Millipore.\38\
---------------------------------------------------------------------------

    \38\ See Danaher Complaint at ] IV(9); European Commission 
Decision at ]] 388, 401.
---------------------------------------------------------------------------

    In the case of columns, the FTC ``estimate[d] the combined firm 
[i.e., Danaher/GE] would have a market share of greater than 45 
percent'' with ``[s]everal fringe firms.'' \39\ In the case of skids, 
the FTC estimated that GE was ``the leading supplier of conventional 
LPLC skids with over 30 percent market share [and that combined] 
Danaher and GE would have an even larger share of the market.'' \40\
---------------------------------------------------------------------------

    \39\ Danaher Complaint at ] IV(9).
    \40\ Id. ] IV(10).
---------------------------------------------------------------------------

    Novasep is one of the ``fringe'' firms that the FTC concluded in 
its GE/Danaher investigation had an insufficient market presence to 
competitively constrain GE/Danaher in these product areas. Novasep 
estimates that its global market share in conventional LPLC columns and 
conventional LPLC skids is de minimis (less than [REDACTED] globally 
and in the U.S.).\41\ Accordingly, the acquisition by Sartorius would 
not risk substantially lessening competition in those products in any 
relevant geographic market.
---------------------------------------------------------------------------

    \41\ Rebecca H. Farrington Letter to Lisa DeMarchi Sleigh, dated 
July 15, 2021 (regarding MU LPLC columns); see also NOVA-000296--
NOVA-000303, at NOVA-000300.
---------------------------------------------------------------------------

c. LPLC Intensified/Continuous Chromatography Systems

    Different technologies have been developed to address biopharma 
customers' needs for faster, more efficient downstream bioprocessing at 
lower cost and bioprocess risk. Sartorius's BioSMB and Novasep's BioSC 
systems each provide a form of ``intensified'' chromatography using 
distinct technologies that addresses different customer needs.\42\ 
Customers have different manufacturing strategies and equipment 
preferences that, in turn, depend on a number of factors, including the 
configuration of their facilities, available and desired footprint, 
type of products (e.g., innovator or biosimilar), stage of production 
(development, clinical or commercial scale), volumes and mix of 
products, efficiencies desired from affinity capture step 
intensification versus other chromatography steps, and labor costs.\43\
---------------------------------------------------------------------------

    \42\ SART_0016281, at 2 (illustrating the different customer 
applications for BioSMB and the Parties' recently launched BioSC-RCC 
system based on customer consumable usage strategy, product 
development stage, and risk tolerance); SART_0145766 (indicating 
that BioSC-RCC is for customers with different preferences or needs 
than multi-column chromatography (``MCC'') systems like BioSMB).
    \43\ See SART_0000606--SART_0000607, at SART_0000606; 
SART_0170114 (illustrating the distinct applications for resin-based 
MCC and membrane-based RCC systems based on customer consumable 
usage strategies, product development status, and customer risk 
tolerance); SART_0115519, at 12 (projecting distinct growth rates 
for BioSC, BioSMB, and BioSC-RCC in Sartorius's July 2021 BioSMB 
Business Plan).
---------------------------------------------------------------------------

i. BioSMB and BioSC Product Differentiation
    BioSMB and BioSC exemplify two distinct approaches to bioprocessing 
intensification that have evolved over the past decade:
     ``Single-step'' intensification of the affinity capture 
chromatography step alone.
    [cir] Other steps in the chromatography process (the virus 
inactivation step and two polishing steps) are achieved using separate 
LPLC batch chromatography equipment.
    [cir] Commercially available systems using ``single step'' 
intensification include BioSMB, Cytiva's PCC (now owned by Danaher), 
YMC/ChromaCon Contichrom Twin, and Tosoh/Semba ProGMP).
     ``Multistep'' intensification of all chromatography steps 
by integrating each chromatography step in a single system and 
continuous process.
    [cir] Commercially available systems include BioSC, PAK 
BioSolutions, and Sepragen QuantaSep).\44\
---------------------------------------------------------------------------

    \44\ Suppliers of multistep systems also include various in-
house systems developed by biopharma companies such as Fujifilm, 
Bayer, Boehringer Ingelheim, and Novartis.
---------------------------------------------------------------------------

    BioSMB (and other single step systems) are designed to maximize the 
productivity of resin at the affinity capture step using a sequential 
multi-column chromatography (``S-MCC'') process. BioSMB offers the 
greatest efficiencies for customers that make biologic drugs such as 
mAbs, which require expensive Protein A resin for purification. Because 
BioSMB only performs the affinity capture step, it may be more 
attractive to customers who are looking to reduce costs and improve 
productivity without replacing their entire downstream bioprocessing 
production line. Customers can still generate significant resin savings 
and increase productivity by replacing their existing batch LPLC 
equipment with BioSMB to perform the affinity capture step without 
having to invest in an entirely new production line (and securing the 
extensive regulatory approvals that are required to do so).
    With its SU flow path technology, BioSMB also is attractive to 
customers who prefer not to undertake intensive cleaning and 
sterilization of MU equipment between process runs. In particular, 
innovator biopharma customers in North America and Europe increasingly 
prefer to use disposable SU flow-kits so that they can quickly switch 
between process runs for different biologic products without time-
consuming cleaning and sterilization, or risk cross-contamination 
between process runs for different drugs.\45\ Some customers explicitly 
make SU technology a requirement in their ``request for proposal'' 
specifications.\46\

[[Page 64488]]

Because BioSC lacks a SU option,\47\ it cannot compete with BioSMB for 
these opportunities.
---------------------------------------------------------------------------

    \45\ See NOVA-001242--NOVA-001755, at NOVA0001572 (``With 
single-use equipment now in routine common use, [biopharma survey] 
respondents may be viewing disposable options from more of an 
economic vs. technological perspective, particularly eliminating 
weeks of manual labor-intensive cleaning and sterilizing stainless 
steel equipment.'').
    \46\ When intensified chromatography systems were first 
introduced to customers as a nascent technology, customers purchased 
benchtop/lab scale models for equipment testing and experimentation. 
Given the small scale of production and the corresponding relative 
ease of changing tubing for SU systems or cleaning the tubing for MU 
systems, customers did not necessarily have a strong preference for 
SU versus MU flow path technology because there is not necessarily a 
significant difference in cost or contamination risks at this scale. 
This was the competitive environment the Commission analyzed in its 
review of the Danaher-GE transaction. Now that large molecule 
innovators are advancing to pilot/process development stage 
production, their preference for SU technology has become more 
pronounced.
    \47\ NOVA-000691--NOVA-000748, at NOVA-000703, NOVA-000707, 
NOVA-000730 (``No Single Use skills'').
---------------------------------------------------------------------------

    In contrast, BioSC's greatest value to customers is its ability to 
continuously perform multi-step, multi-column chromatography (``MS-
MCC'').\48\ Although it is technically capable of performing S-MCC 
alone, most customers have placed orders without the S-MCC 
configuration because this would eliminate the system's ability to 
continuously perform multiple chromatography steps in an MS-MCC 
process.\49\ To perform the affinity capture step, MS-MCC typically 
uses a simplified, less efficient form of multi-column intensification 
or a conventional batch process, which is not as efficient as BioSMB. 
BioSC's productivity benefits are largely achieved through the 
integration of the entire downstream chromatography process in a single 
system using an onboard software suite to coordinate each 
chromatography step.\50\ BioSC's integrated system also eliminates time 
consuming (and productivity reducing) intermediate steps such as 
product storage in holding tanks between chromatography processes that 
are required for single-step, standalone systems such as BioSMB.\51\
---------------------------------------------------------------------------

    \48\ See Rebecca H. Farrington Letter to Lisa DeMarchi Sleigh, 
dated April 26, 2021, at 3-4 (regarding BioSC chromatography 
processes).
    \49\ Id. at 3. A BioSC system configured for MS-MCC in Novasep's 
factory cannot be ``switched'' to the S-MCC process that BioSMB uses 
by a customer. Customers must ship the equipment back to the Novasep 
factory for modification and, in practice, they have not done so. 
Id.
    \50\ See SART_0002159--SART_0002187, at SART_0002171.
    \51\ See Sartorius BioSMB Technical Discussion Presentation: 
Meeting with FTC (Apr. 22, 2021), at 9.
---------------------------------------------------------------------------

    BioSC is an attractive option for customers who have the 
flexibility to implement a new downstream production line or are 
building a new manufacturing facility. BioSC's integrated system 
reduces manufacturing footprint by reducing the size (and associated 
operational costs) of the sterile ``clean rooms'' required to produce 
biologics.\52\ In addition, certain customers may prefer BioSC's MU 
technology if, for example, they are producing larger product runs 
(e.g., biosimilars), switching between products infrequently, and/or 
are located in regions where labor costs for cleaning and sterilization 
of MU equipment are lower (e.g., Southeast Asia).\53\
---------------------------------------------------------------------------

    \52\ See Rebecca H. Farrington Letter to Lisa DeMarchi Sleigh, 
dated April 26, 2021, at 2 (regarding BioSC chromatography 
processes).
    \53\ See, e.g., NOVA-001210--NOVA-001241; NOVA-001759--NOVA-
001800; NOVA-001756--NOVA001758; NOVA-001191--NOVA-001207.
---------------------------------------------------------------------------

    Because BioSMB and Novasep BioSC are highly differentiated products 
that provide process intensification in different ways, customers 
generally do not view them as close substitutes, particularly at 
clinical and manufacturing scales.
ii. BioSC Has Failed To Penetrate the U.S. and Its Global Sales Are 
Declining
    Since BioSC's launch in 2015, Novasep has sold only a few lab scale 
units in the U.S.\54\ To the extent that BioSC Lab sales are viewed as 
an indication of potential future BioSC sales at commercial scale, 
Novasep lacks an installed base of lab scale equipment to generate 
future sales. Novasep has faced challenges convincing customers to 
scale up to BioSC's larger (clinical or manufacturing scale systems), 
in part because Novasep's product family does not have a simple scale-
up pathway.\55\
---------------------------------------------------------------------------

    \54\ Novasep manufactures the BioSC system at three different 
scales: Lab, pilot/clinical, and manufacturing. Bioprocesses that 
are investigated on BioSC Lab are ``scaled up'' (i.e., increased in 
size/volume) to the larger BioSC Pilot system for clinical 
development (although BioSC faces challenges when scaling up that 
Sartorius plans to address in its redesign of the three scales of 
the system), and ultimately to BioSC Manufacturing system for 
commercial production.
    \55\ See Bates White's CRM Data Analysis Presentation and 
exhibits, dated May 26, 2021, at 8.
---------------------------------------------------------------------------

    BioSC's lack of sales in the U.S. is attributable to several 
challenges that Sartorius is uniquely placed to overcome and to do so 
quickly, given its extensive experience working with the BioSC 
platform.\56\ First, Novasep does not have an established reputation as 
an LPLC supplier and is relatively unknown to the North American 
biopharma industry for LPLC. Second, unlike BioSMB, Novasep's BioSC 
product family does not provide customers an easily achievable scale-up 
pathway because the system architecture of the BioSC lab scale model, 
which biopharma customers can use to test the BioSC proof of concept, 
differs significantly from that of BioSC Pilot and BioSC M, which are 
used for drug development and manufacture.\57\ Third, innovator 
biotechnology companies in North America prefer to purchase from 
longstanding suppliers that have significant local sales and support 
infrastructure. Novasep has only [REDACTED] salespeople and [REDACTED] 
service technicians in the U.S. to support all of its HPLC and LPLC 
product lines.\58\ In contrast, Sartorius's specialized chromatography 
sales and service ``task force'' already includes 11 individuals in the 
U.S. supporting its LPLC chromatography products alone, and Sartorius 
is planning to expand the team. Fourth, there is an increasing customer 
preference in the U.S., particularly at commercial scale, to use SU 
flow-path technology (which Novasep does not have).\59\ Fifth, BioSC's 
software, which controls and coordinates the MS-MCC process, has 
experienced challenges and the system will benefit from Sartorius's 
expertise in software and process automation.\60\
---------------------------------------------------------------------------

    \56\ See NOVA-000691--NOVA-000748, at NOVA-000738 (Novasep's 
customer sales, service, and support infrastructure is 
underdeveloped.).
    \57\ See NOVA-001208--NOVA-001209 (explaining that BioSC Lab 
does not scale up to BioSC Pilot).
    \58\ See Novasep's Voluntary Access Letter Response dated 
September 17, 2021, at 25.
    \59\ See SART_0001180--SART_0001181, at SART_0001180; 
SART_0003306 (providing Sartorius' projections of customer 
preference for the SU version of BioSC RCC); SART_0168117, at 17 
(June 2021 Business Review indicating ``Growth to achieve 2025 
driven by steady-increased Multi-Use System and explosive-increased 
Single-Use System''); see also NOVA-000872, NOVA-000881 (Budget 2020 
BU Process Solutions).
    \60\ See, e.g., NOVA-VAL-0000079; NOVA-VAL-0014556; NOVA-VAL-
0018504; NOVA-VAL-0025513; NOVA-VAL-0027911; NOVA-VAL-0063924; NOVA-
VAL-0063984; NOVA-VAL-0073282; NOVA-VAL-0073557; NOVA-VAL-0075029.
---------------------------------------------------------------------------

    Despite the potential benefits of the system, the trajectory of 
Novasep's BioSC sales over the past several years has been declining 
and its sales prospects are unlikely to improve without necessary 
investment and improvements that Sartorius is uniquely placed to 
provide.\61\ In order to achieve commercial adoption and deliver its 
potential benefits to customers, BioSC requires the investment and 
innovations that Sartorius is planning to provide once it owns the 
platform including, inter alia, updating and redesigning the systems to 
a more ``off the shelf'' design and streamlined manufacturing process 
at a lower cost, the development of a SU flow-path and software 
improvements, as well as the support of Sartorius's U.S. and global 
sales and service infrastructure.
---------------------------------------------------------------------------

    \61\ See F. Schaeffer Letter to Lisa DeMarchi Sleigh, dated July 
9, 2021, at 3 (regarding BioSC scale up and sales).

---------------------------------------------------------------------------

[[Page 64489]]

iii. BioSMB and BioSC Virtually Never Compete Head-to-Head
    Because BioSMB and BioSC utilize different technologies and 
approaches that meet different customer needs, there has been very 
little head-to-head competition between them since their lab scale 
systems were launched. Indeed, the Parties have identified only one 
instance of BioSMB and BioSC pursuing the same opportunity at 
commercial (i.e., clinical or manufacturing) scale. This was an 
opportunity to sell to a potential customer located outside of the 
U.S., which neither company won.
    Because BioSMB and BioSC are highly differentiated products that 
are very rarely in direct competition in new sales opportunities,\62\ 
there is no practical risk of unilateral price effects from the 
acquisition.\63\ The Parties' win/loss data confirms that BioSMB and 
BioSC virtually never compete directly \64\ and that any attempted 
unilateral price increase for either product post-merger would be 
unprofitable.\65\
---------------------------------------------------------------------------

    \62\ ``In differentiated product industries, some products can 
be very close substitutes and compete strongly with each other, 
while other products are more distant substitutes and compete less 
strongly. . . . The extent of direct competition between the 
products sold by the merging parties is central to the evaluation of 
unilateral price effects.'' Dep't of Just. & Fed. Trade Comm'n, 
Horizontal Merger Guidelines Sec.  6.1 (2010) [hereinafter 
Horizontal Merger Guidelines].
    \63\ ``Unilateral price effects are greater, the more the buyers 
of products sold by one merging firm consider products sold by the 
other merging firm to be their next choice. The Agencies consider 
any reasonably available and reliable information to evaluate the 
extent of direct competition between the products sold by the 
merging firms. This includes documentary and testimonial evidence, 
win/loss reports and evidence from discount approval processes, 
customer switching patterns, and customer surveys.'' Id.
    \64\ See Bates White's CRM Data Analysis Presentation and 
exhibits, dated May 26, 2021, at 8.
    \65\ ``A merger between firms selling differentiated products 
may diminish competition by enabling the merged firm to profit by 
unilaterally raising the price of one or both products above the 
pre-merger level. Some of the sales lost due to the price rise will 
merely be diverted to the product of the merger partner and, 
depending on relative margins, capturing such sales loss through 
merger may make the price increase profitable even though it would 
not have been profitable prior to the merger.'' Horizontal Merger 
Guidelines at Sec.  6.1.
---------------------------------------------------------------------------

iv. Sartorius Must Continue To Offer Multiple Platforms and Innovate To 
Displace Incumbent Batch LPLC Suppliers and Meet Increasing Process 
Intensification Competition
    Sartorius views the acquisition of the multistep BioSC system as 
filling a gap in its chromatography portfolio to meet customer demand 
for an integrated continuous chromatography system that BioSMB's 
single-step system does not provide. Sartorius has forecast distinct 
customer demand (and growth rates) for both BioSMB and BioSC 
platforms.\66\
---------------------------------------------------------------------------

    \66\ See SART_0115519, at 12 (projecting distinct growth rates 
for BioSC, BioSMB, and BioSC-RCC in Sartorius's July 2021 BioSMB 
Business Plan); SART_0000601--SART_0000605 (regarding Sartorius's 
plans to continue to support both platforms).
---------------------------------------------------------------------------

    Sartorius has already made investments in the BioSC-RCC and BioSMB 
platforms.\67\ Once the transaction is approved, Sartorius will be able 
to make necessary investments in BioSC to make it a commercially 
attractive option for customers. As a new entrant in the chromatography 
equipment business, Sartorius needs to overcome the incumbency 
advantages of the dominant batch LPLC chromatography equipment 
suppliers by convincing customers that it is worth replacing their 
legacy batch systems with superior Sartorius equipment. Sartorius has a 
better prospect of convincing customers across the board to make the 
switch if it can offer multiple options for intensification in a range 
of systems and approaches that meet different customer priorities and 
needs.
---------------------------------------------------------------------------

    \67\ Sartorius also completed an extensive, in-house sales 
training program and launched a marketing campaign in March 2021 to 
promote the BioSMB system to prospective customers whom it had 
identified might be interested in moving from conventional batch 
processing to a continuous chromatography system. See generally 
SART_0016472.
---------------------------------------------------------------------------

    The Proposed Transaction also will combine Sartorius's and 
Novasep's complementary technologies, know-how, and engineering 
expertise that will accelerate the development of next generation 
systems and innovations, and meet escalating competition in intensified 
chromatography processing.\68\ Intensification of downstream processing 
is a strategic focus of biopharma companies, which have an increasing 
number of competitive options through their own product development 
efforts, as well as strategic combinations and investments by their 
supplier base:
---------------------------------------------------------------------------

    \68\ See Horizontal Merger Guidelines Sec.  6.4 (``The Agencies 
also consider whether the merger is likely to enable innovation that 
would not otherwise take place, by bringing together complementary 
capabilities that cannot be otherwise combined or for some other 
merger-specific reason.'').
---------------------------------------------------------------------------

    Tosoh/Semba: In January 2019, Tosoh Corporation increased its 
investment in U.S.-based Semba Biosciences, Inc. in pursuit of its goal 
to become a full range solutions provider for biopharma 
purification.\69\ The investment enhanced Semba's ability to market and 
innovate with its SU lab and process development scale LPLC continuous 
chromatography systems, and Tosoh's scale and resources, which include 
a significant resins business, allowed it to commercialize its first 
commercial scale SU LPLC continuous chromatography system this 
year.\70\
---------------------------------------------------------------------------

    \69\ Tosoh Corporation Invests in Semba Biosciences, Inc., Tosoh 
(Jan. 10, 2019), https://www.tosoh.com/news-press/news-releases/2019/tosoh-corporation-invests-in-semba-biosciences-inc.
    \70\ New ProGMP 150 System, Semba Biosciences, https://sembabio.com/progmp-150-system/#1617729557380-f5d67fe8-6d6a (last 
visited Oct. 22, 2021).
---------------------------------------------------------------------------

    YMC/ChromaCon: In April 2019, YMC Co., Ltd. acquired ChromaCon AG, 
a manufacturer of LPLC continuous chromatography systems.\71\ As a 
result, ChromaCon has been able to leverage YMC's expertise in resin 
and packed columns to enhance its lab, pilot, and commercial scale LPLC 
continuous chromatography systems.\72\ In July 2020, the U.S. Food and 
Drug Administration purchased a ChromaCon LPLC continuous 
chromatography system for evaluation, signaling its interest and 
confidence in ChromaCon's equipment.\73\
---------------------------------------------------------------------------

    \71\ YMC Acquires Chromacon, ChromaCon (Apr. 9, 2019), https://www.chromacon.com/en/news/ymc-acquires-chromacon.
    \72\ Contichrom TWIN--GMP Scale-up equipment, ChromaCon, https://www.chromacon.com/en/products/gmp-scale-up-equipment (last visited 
Oct. 22, 2021).
    \73\ FDA selects twin-column chromatography system by YMC 
ChromaCon for evaluation, ChromaCon (July 2020), https://www.chromacon.com/resources/public/lava3/media/kcfinder/files/FDA%20orders%20Twin%20Column%20Chromatography%20of%20YMC%20Press%20Release%2007F2020.pdf.
---------------------------------------------------------------------------

    Sepragen: Sepragen, a U.S.-based firm, offers a complete product 
portfolio including resins, columns, and MU and SU chromatography 
systems at lab, pilot, and commercial scales.\74\ Sepragen has 
developed and sold MU LPLC continuous chromatography systems and 
recently added a lab scale chromatography system with a SU flow path to 
its product portfolio.\75\
---------------------------------------------------------------------------

    \74\ Products Overview, Sepragen, https://www.sepragen.com/Products.html (last visited Oct. 22, 2021).
    \75\ QuantaSep Single Use, Sepragen, https://www.sepragen.com/Products-Chromatography-Systems-Single-Use.html (last visited Oct. 
22, 2021).
---------------------------------------------------------------------------

    Repligen/ARTeSYN: In October 2020, Repligen Corporation announced 
its acquisition of ARTeSYN Biosolutions.\76\ ARTeSYN produces 
engineered-to-order (``ETO'') SU continuous chromatography systems at 
different

[[Page 64490]]

scales, which Repligen is now actively marketing.\77\ As a leading 
resin supplier to biopharma companies in the U.S. and globally, 
Repligen has the financial resources and customer relationships to 
commercialize and improve ARTeSYN's continuous chromatography 
technology. For example, Repligen produces pre-packed columns, which 
are well suited to ARTeSYN systems. Repligen plans to continue 
developing ARTeSYN's single-use solutions as part of its portfolio.
---------------------------------------------------------------------------

    \76\ Repligen Corporation Announces Agreement to Acquire 
Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes 
Acquisition of Non-Metallic Solutions, Repligen (Oct. 27, 2020), 
https://repligen.q4ir.com/news/news-details/2020/Repligen-Corporation-Announces-Agreement-to-Acquire-Bioprocess-Systems-Innovator-ARTeSYN-Biosolutions-and-Completes-Acquisition-of-Non-Metallic-Solutions/default.aspx.
    \77\ ARTeSYN Chromatography Systems, Repligen, https://www.repligen.com/technologies/engineered-systems/chromatography-systems#collapse1-2 (last visited Oct. 22, 2021).
---------------------------------------------------------------------------

    Merck Millipore: Merck Millipore is leveraging a platform called 
BioContinuum to provide a form of intensified processing using 
chromatography equipment based on the company's ``Mobius'' concept. 
Merck Millipore has announced a collaboration in intensified downstream 
processing with Transcenta (formerly Just Bio).\78\
---------------------------------------------------------------------------

    \78\ MilliporeSigma and Transcenta Collaborate to Advance 
Continuous Biomanufacturing, Make the `Facility of the Future' a 
Reality, MilliporeSigma (Nov. 7, 2020), https://www.emdmillipore.com/US/en/20201106_153338?bd=1.
---------------------------------------------------------------------------

    PAK BioSolutions: PAK BioSolutions is a new, U.S.-based, 
chromatography equipment entrant that was founded in 2018. In 2021, PAK 
introduced a SU pilot scale multistep intensified chromatography system 
that can perform MS-MCC in a manner similar to BioSC.\79\
---------------------------------------------------------------------------

    \79\ The PAK System, PAK BioSolutions, https://www.pakbiosolutions.com/the-pak-system/ (last visited Oct. 22, 
2021).
---------------------------------------------------------------------------

    In sum, competition in LPLC continuous chromatography systems and 
intensified processing approaches has significantly increased since the 
Danaher-GE transaction.\80\ Larger players are investing in smaller 
competitors and developing their own products, and customers continue 
to develop their own in-house solutions.\81\
---------------------------------------------------------------------------

    \80\ SART_0009787--SART_0009826, at pp. 11-12 (comparing BioSC 
to PAK BioSolutions, a ``[n]ew entrant . . . offering SU equivalent 
to BioSC,'' and identifying biopharma companies developing systems 
in-house and noting that more biopharma companies are utilizing 
multistep processes).
    \81\ MilliporeSigma and Transcenta Collaborate to Advance 
Continuous Biomanufacturing, Make the `Facility of the Future' a 
Reality, (Nov. 7, 2020), MilliporeSigma, https://www.emdmillipore.com/US/en/20201106_153338?bd=1.
---------------------------------------------------------------------------

    Following the transaction, Sartorius will continue to face 
competition from a range of intensified LPLC system suppliers 
including:
     At least six, well-capitalized suppliers that are actively 
marketing products in the chromatography intensification space: Danaher 
(Cytiva), Tosoh/Semba, YMC/ChromaCon, Sepragen, Repligen/ARTeSYN, and 
PAK BioSolutions;
     incumbent batch LPLC equipment suppliers, such as Merck 
Millipore, which are entering the space;
     emerging Chinese suppliers, such as Lisure Science; and
     customers who are continuing to develop their own 
intensification technologies in-house.
    Intensified/continuous chromatography is an emerging area with a 
range of technologies. No single approach has achieved broad adoption 
at this time. To achieve commercial success, Sartorius will need to 
continue to innovate and demonstrate greater efficiencies to convince a 
critical mass of customers to adopt its products in place of incumbent 
conventional LPLC batch systems and other competing intensification 
solutions. The proposed acquisition will enhance Sartorius's ability to 
continue to successfully innovate in this growing and increasingly 
competitive field and to develop next generation solutions to meet 
industry needs for cost-effective, biologic drug development and large-
scale production.

IV. If the Proposed Acquisition Is Not Approved, the Parties' Existing 
and Future Innovations Will Be Lost and Customers and Consumers Will Be 
Harmed

    In developing BioSC-RCC, the Parties have created a unique new 
product--a membrane-based intensified chromatography system that 
employs RCC as an alternative to resin-based systems.\82\ The product 
is still in the testing phase and no sales have been made as yet. 
Sartorius has concluded that it needs to develop and launch a BioSC-RCC 
system with a SU flow-path option for the BioSC-RCC concept to achieve 
commercial success. A SU option would be preferred by many customers 
who are concerned about maintaining purity and low bioburden risk, 
while achieving quick turnaround times between batches.\83\ However, 
Sartorius has no incentive to invest in this innovation without any 
right to manufacture or market the system. Developing and launching 
BioSC-RCC with a SU option will not be feasible unless Sartorius is 
able to acquire the Novasep equipment business.
---------------------------------------------------------------------------

    \82\ Membrane capsules and cassettes are an emerging technology 
that offer the potential for greater production efficiencies than 
conventional resin-based chromatography systems. See SART_0002159--
SART_0002187, at SART_0002173 (comparing projected customer cost 
savings of BioSC-RCC to GE/Cytiva's conventional LPLC batch 
equipment).
    \83\ See SART_0000487--SART_0000498, at SART_000498; 
SART_0003206 (indicating Sartorius's expectation that BioSC-RCC 
would displace less-efficient, traditional batch equipment, notably 
GE/Cytiva's dominant conventional LPLC batch equipment and providing 
Sartorius' projections, showing sales of the SU version of BioSC-RCC 
exceeding the MU version over time); see also SART_0003306; 
SART_0168117, at 17.
---------------------------------------------------------------------------

    If Sartorius were unable to acquire Novasep's chromatography 
equipment business, the innovations achieved by the collaboration are 
unlikely to be successfully commercialized and planned innovations, 
such as the BioSC-RCC SU version, will not be achieved. If the sale of 
the business to Sartorius is not approved, it would be transferred to 
Novasep's private investor shareholder until it could be divested. 
Uncertainty over the future ownership of the business would stall 
further investment and development by both Sartorius and the Novasep 
chromatography equipment team (which already is operating with 
significant resource constraints). The fruits of the Parties' 
collaboration would be lost and ultimately the collaboration would end.
    Furthermore, if the Proposed Transaction does not close before year 
end, the business would be transferred to NVHL S.A., which would risk 
business deterioration and attrition of critical employees. The further 
uncertainty that would result from a transfer of the business to NVHL 
S.A. would risk employee attrition with further adverse business 
impacts. It would also undermine customers' confidence in the Novasep 
equipment business and its ability to support long-term investments in 
its equipment. In particular, biopharma customers, who prioritize 
security of supply and long-term business continuity when making 
equipment purchasing decisions, understandably would be reluctant to 
invest in Novasep equipment while the business' ownership and future 
remains uncertain. Thus, in addition to depriving the business of the 
resources needed to invest in, market, and sell its products that its 
acquisition by Sartorius would provide, this standalone scenario would 
likely lead to a reduction of revenue further undermining the 
competitiveness and prospects for the business.
    Once the transaction is approved, Sartorius will be able to 
progress its planned investments in BioSC, including development of a 
SU flow-path, redesign of the BioSC family so that it scales up easily 
and without extensive and costly revalidation studies, redesign of the 
current ETO BioSC M system as an off-the-shelf system to improve 
customer delivery

[[Page 64491]]

times,\84\ and redesign of BioSC's software, which has been unreliable 
and rendered some systems inoperable.\85\ The Proposed Transaction will 
allow these innovations to be achieved and will accelerate product 
development by enabling each company's engineering personnel to work 
together under one roof \86\ with a unified and stronger strategic 
focus on developing these products more quickly and cost-
effectively.\87\
---------------------------------------------------------------------------

    \84\ The average time from order to delivery for a BioSC system 
is significantly longer than for a BioSMB system, in part because 
Sartorius has a superior manufacturing process and efficiencies, and 
many of Novasep's products are manufactured on an ETO basis, which 
is more costly and time-consuming. SART_0000464--SART0000471, at 
SART0000468; see also SART_0001130--SART_1177, at SART_0001142 
(regarding Sartorius's plans for significant additional investment 
in product development); id. at SART_0001151 (regarding Sartorius's 
acquisition business case, which includes a multiyear investment in 
the development of BioSC M).
    \85\ See Why Novasep is Not a Competitive Constraint--White 
Paper Prepared for the U.S. Federal Trade Commission, dated June 4, 
2021, at 17, n.25 (regarding BioSC software challenges).
    \86\ See SART_0001130--SART_0001177, at SART_0001136; 
SART_0002571--SART_0002591, at SART_0002576 (outlining Sartorius' 
integration plans, including highlighting the creation of a 
centralized research and development site as ``priority #1'' as it 
will benefit from ``automation expertise for [the] full 
chromatography portfolio,'' the ``use of existing supplier network/
cooperation partner--short distances (250km radius) to established 
suppliers/sub-contractors of BioSMB/Allegro systems,'' ``[c]lose 
collaboration with French [Sartorius] colleagues in Aubagne for 
single-use systems,'' and the ``[o]pportunity to hire former Pall 
people because of close proximity to Dreieich'').
    \87\ Although Sartorius's research and development plans confirm 
that it intends to do much more than maintain the status quo for 
Novasep's products, Sartorius also made specific guarantees to 
maintain and invest in Novasep at least at current levels for a 
three-year period in connection with French foreign investment 
approval, which demonstrates its commitment to Novasep's 
technologies and employees. See Andrew S. Wellin Letter to Lisa 
DeMarchi Sleigh, dated July 1, 2021 (regarding Sartorius's 
commitments in connection with French foreign investment approval of 
the Proposed Transaction).
---------------------------------------------------------------------------

    Combining Sartorius and Novasep technologies, IP, engineering 
personnel, and know-how also will accelerate innovation in the BioSMB 
product line. Planned innovations include value-engineering BioSMB's SU 
flow-kits to reduce their cost, developing BioSMB-specific applications 
data for additional types of therapies, and line extensions, such as 
the planned, [REDACTED].\88\
---------------------------------------------------------------------------

    \88\ See SART_0000487--SART_0000498, at SART_0000496; 
SART_0009752, at SART_0009754-55 (illustrating Sartorius' 
development plans for BioSMB); SART_0153310, at 14 (listing ongoing 
BioSMB PD improvement projects).
---------------------------------------------------------------------------

    The Proposed Transaction will ensure that Novasep's products are 
effectively manufactured, marketed, and supported by an innovative 
supplier with the infrastructure that biopharma customers rely on to 
make long-term capital investments in these products. With the support 
of Sartorius's global manufacturing, supply chain, sales, and service 
infrastructure,\89\ customers will have the confidence to purchase 
Novasep equipment as a long-term capital investment. All of these 
benefits will be particularly pronounced in the U.S., where Novasep has 
been unable to successfully commercialize BioSC or its other LPLC 
product lines.
---------------------------------------------------------------------------

    \89\ Currently, Sartorius has 306 sales and service employees in 
the BPS organization. Following the closing of the Danaher/Pall 
divestiture, Sartorius created a 20-person chromatography ``task 
force'' dedicated solely to chromatography sales with a special 
focus on intensified/continuous chromatography equipment. Over half 
of Sartorius's chromatography task force is located in the U.S.
---------------------------------------------------------------------------

V. Request for Confidential Treatment

    This petition, including its related documents, contains certain 
confidential and competitively sensitive business information relating 
to Sartorius, Novasep, and the Proposed Transaction. Disclosure of such 
confidential information may prejudice Sartorius and Novasep, and cause 
harm to the ongoing competitiveness of both companies. Pursuant to 
Sections 2.41(f)(4) and 4.9(c) of the FTC's Rules of Practice and 
Procedure,\90\ Sartorius has redacted such information from the public 
version of this application, and requests confidential treatment for 
such redacted information under Section 4.10(a)(2) of the FTC's Rules 
of Practice and Procedure \91\ and Sections 552(b)(4) and (b)(7) of the 
Freedom of Information Act.\92\ In the event that a determination is 
made that any material marked as confidential is not subject to 
confidential treatment, Sartorius requests that the FTC provide prompt 
notice of that determination and adequate opportunity to appeal such a 
decision.
---------------------------------------------------------------------------

    \90\ 16 CFR 2.41(f)(4) and 4.9(c).
    \91\ 16 CFR 4.10(a)(2).
    \92\ 5 U.S.C. 552(b)(4), 552(b)(7).

---------------------------------------------------------------------------
Respectfully submitted,

/s/Fiona A. Schaeffer

Fiona A. Schaeffer,
Andrew S. Wellin,
MILBANK, LLP, 55 Hudson Yards, New York, NY 10001.

Counsel for Sartorius Stedim Biotech, S.A.

    Dated: October 28, 2021.

[FR Doc. 2021-25150 Filed 11-17-21; 8:45 am]
BILLING CODE 6750-01-P